Pharmacologic challenges in Alzheimer disease and normal controls: Cognitive modeling in humans

Alzheimer Disease and Associated Disorders

Volumn 11, Issue SUPPL. 4, 1997, Pages

  Sunderland, T ^a   Molchan, S E ^a   Little, J T ^a   Bahro, M ^a   Putnam, K T ^a   Weingartner, H ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Cholinergic; Combination; Deficit; Nicotinic; Pharmacomodeling; Serotonergic

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROTRANSMITTER; NICOTINIC RECEPTOR BLOCKING AGENT; SEROTONIN ANTAGONIST;

ALZHEIMER DISEASE; AMNESIA; ARTICLE; BEHAVIOR DISORDER; CHOLINERGIC SYSTEM; COGNITIVE DEFECT; DEPRESSION; DOPAMINERGIC SYSTEM; HALLUCINATION; HUMAN; PRIORITY JOURNAL; PSYCHOSIS; THINKING;

AGED; ALZHEIMER DISEASE; BRAIN; DRUG SYNERGISM; HUMANS; MEMORY, SHORT-TERM; MODELS, NEUROLOGICAL; NEUROTRANSMITTER AGENTS; PSYCHOTROPIC DRUGS; RECEPTORS, CHOLINERGIC; RECEPTORS, DOPAMINE; RECEPTORS, MUSCARINIC; RECEPTORS, NICOTINIC; RECEPTORS, SEROTONIN;

EID: 0030680177     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders-revised. 4th ed. Washington, DC: American Psychiatric Association. 1994.
2. Bowen DM, Allen SJ, Benton JS, et al. Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease. J Neurochem 1983;41:266-72.
3. Broocks A, Little JT, Martin A, et al. The influence of ondansetron and m-CPP on scopolamine-induced cognitive, behavioral and physiological responses in young healthy controls. Biol Psychiatry (in press).
4. Buschke H. Selective reminding for analysis of memory and learning. J Verb Learn Verb Behav 1973;12:543-50.
5. Carey GJ, Costall B, Domeney AM, et al. Ondansetron and arecoline prevent scopolamine-induced cognitive deficits in the marmoset. Pharm Biochem Behav 1992;42:75-83.
6. Kahn RS, Wetzler S. m-Chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatry 1991;30:1139-66.
7. Lawlor BA, Mellow AM, Sunderland T, et al. A pilot study of serotonergic system responsivity in Alzheimer's disease. Psychopharmacot Bull 1988;24:127-9.
8. Lawlor BA, Radcliff J, Molchan SE, et al. A pilot placebo-controlled study of trazodone and buspirone in Alzheimer's disease. Int J Geriatr Psychiatry 1994;9:55-9.
9. Lawlor BA, Sunderland T, Mellow AM, et al. Hyperesponsivity to the serotonin agonist m-chlorophenylpiperazine in Alzheimer's disease: a controlled study. Arch Gen Psychiatry 1989a;46:542-9.
10. Lawlor BA, Sunderland T, Mellow AM, et al. A preliminary study of the effects of intravenous m-chlorophenylpiperazine, a serotonin agonist in elderly subjects. Biol Psychiatry 1989b;25:679-86.
11. Levin ED, McGuck SR, South D, Butcher LL. Effects of combined muscarinic and nicotinic blockade on choice accuracy in the radial-arm maze. Behav Neural Biol 1989;51:270-7.
12. Little JT, Johnson D, Minichiello M, et al. Combined nicotinic and muscarinic blockade in normal elderly volunteers: cognitive, behavioral and physiologic responses (submitted).
13. 3Hserotonin release in different rat brain areas. Eur J Pharmacol 1986;129: 353-7.
14. Molchan SE, Vitiello B, Minichiello M, et al. Reciprocal changes in psychosis and mood after physostigmine in a patient with Alzheimer's disease. Arch Gen Psychiatry 1991;48:1113-4.
15. Murphy DL, Lesch KP, Aulakh CS, et al. Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature and cardiovascular effects in humans. Pharmacol Rev 1991;43:527-52.
16. Murphy DL, Pigott TA, Grady TA, et al. Affective, behavioral, and other non-endocrine physiologic responses to 5-HT1/2 agonists and antagonists in humans. Eur Neuropsychopharmacol 1993;3:308-9.
17. Palmer AM, Francis PT, Benton JS, et al. Presynaptic serotonergic dysfunction in patients with Alzheimer's disease. J Neurochem 1987;48:8-15.
18. Perry EK, Perry RH, Blessed G, et al. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1977;1:89.
19. Schwartz J-C, Levesque D, Martres M-P, et al. Dopamine D3 receptors: basic and clinical aspects. Clin Neuropharmacol 1993;4:295-314.
20. Sunderland T, Molchan S, Lawlor B, et al. A strategy of "combination chemotherapy" in Alzheimer's disease: rationale and preliminary results with physostigmine plus deprenyl. Int Psychogeriatr 1992; 4(suppl 2):S291-309.
21. Sunderland T, Tariot PN, Newhouse PA. Differential responsivity of mood, behavior and cognition to cholinergic agents in elderly neuropsychiatric populations. Brain Res Rev 1988;13:371-89.
22. Tariot PN, Cohen RM, Sunderland T, et al. L-deprenyl in Alzheimer's disease: preliminary evidence for behavioral change with monoamine oxidase B inhibition. Arch Gen Psychiatry 1987;44:427-33.
23. Vitiello B, Martin A, Hill J, et al. Cognitive and behavioral effects of cholinergic, dopaminergic and serotonergic blockade in humans. Neuropsychopharmacology 1997;16:15-24.
24. White P, Godhadt MJ, Keet JP, et al. Neocortical cholinergic neurons in elderly people. Lancet 1977;1:668-71.